China, Sept. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Arm, Exploratory Clinical Study of Adebelimumab in Combination with the AG Regimen for the Treatment of Potentially Resectable Cholangiocarcinoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133648
Registration Time: 2026/09/30
Type: Interventional study
Primary Sponsor: Shandong Provincial Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340053
Published by HT Digital Content Services with permission from Health Daily Digest....